← Back to Emcure Pharmaceuticals Ltd. overview
Emcure Pharmaceuticals Ltd. — 10-Year Financials
Annual P&L, balance sheet, and key ratios from public BSE/NSE filings.
| Period | Revenue | Net Profit | EPS (₹) | Total Assets | Shareholder Equity | ROE (%) | ROCE (%) | D/E | Net Margin (%) |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹7,808 cr | ₹681 cr | ₹36.43 | ₹8,233 cr | ₹4,446 cr | 15.32% | 20.32% | 0.23x | 8.73% |
| FY2024 | ₹6,582 cr | ₹498 cr | ₹27.57 | ₹7,806 cr | ₹2,952 cr | 16.87% | 17.55% | 0.79x | 7.57% |
| FY2023 | ₹5,931 cr | ₹532 cr | ₹29.43 | ₹6,673 cr | ₹2,501 cr | 21.27% | 18.82% | 0.93x | 8.97% |
| FY2022 | ₹5,766 cr | ₹662 cr | ₹36.63 | ₹6,063 cr | ₹1,988 cr | 33.32% | 26.28% | 1.12x | 11.48% |
Revenue: Total income from operations (₹ crore).
EPS: Earnings per share (₹), basic.
ROE: Net profit / average shareholder equity.
ROCE: EBIT / capital employed.
D/E: Total debt / shareholder equity.
Net Margin: Net profit as a % of revenue.
All figures sourced from public BSE/NSE filings. Ratios are pre-computed estimates and may differ from primary filings due to rounding.
Educational content — not investment adviceAll financial data is sourced from public filings and shown here for educational purposes only. EquitiesIndia.com is not a SEBI-registered Investment Adviser or Research Analyst. Nothing on this page constitutes a recommendation or solicitation to transact in any security. All data is at least 90 days old. Past performance is not indicative of future results.